Top UK regulator foresees upswing in use of parallel advice scheme
This article was originally published in SRA
Executive Summary
The UK Medicines and Healthcare Products Regulatory Agency is confident that more pharmaceutical companies will make use before long of the parallel scientific advice scheme it has in place with the health technology assessment (HTA) body, NICE.